UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


OMB APPROVAL
OMB NUMBER: 3235-0145
Expires: December 31, 2005
Estimated average burden
hours per response....11

SCHEDULE 13G/A

Under the Securities Exchange Act of 1934
(Amendment No._5___ )*

ALSERES PHARMACEUTICALS, INC
(Name of Issuer)

COMMON STOCK
(Title of Class of Securities)

021152103
(CUSIP Number)

12/31/2011
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:

[] Rule 13d-1(b)
[X] Rule 13d-1(c)
[] Rule 13d-1(d)


*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


CUSIP No. 021152103



--------------------------------------------------------------------------------
 1. NAME OF REPORTING PERSON(S)
 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON(S)

 INGALLS & SNYDER VALUE PARTNERS, LP
 13-3694561


--------------------------------------------------------------------------------
 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 (a) [ ]
 (b) [ ]


--------------------------------------------------------------------------------
 3. SEC USE ONLY




--------------------------------------------------------------------------------
 4. CITIZENSHIP OR PLACE OF ORGANIZATION


 NEW YORK STATE

--------------------------------------------------------------------------------
 NUMBER OF 5. SOLE VOTING POWER
 SHARES 3,403,969
BENEFICIALLY --------------------------------------------------------------
 OWNED BY 6. SHARED VOTING POWER
 EACH 0
 REPORTING --------------------------------------------------------------
 PERSON 7. SOLE DISPOSITIVE POWER
 WITH 0
--------------------------------------------------------------
 8. SHARED DISPOSITIVE POWER

 3,403,969
--------------------------------------------------------------------------------
 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 3,403,969
--------------------------------------------------------------------------------
 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*



--------------------------------------------------------------------------------
 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 9.99%
--------------------------------------------------------------------------------
 12. TYPE OF REPORTING PERSON*

 PN
--------------------------------------------------------------------------------


Item 1. (a) Name of Issuer:

 ALSERES PHARMACEUTICALS, INC.
 --------------------------------------------------------------
 (b) Address of Issuer's Principal Executive Offices:

 239 SOUTH STREET
 HOPKINTON, MA 01748
 --------------------------------------------------------------
Item 2. (a) Name of Person Filing:


 INGALLS & SNYDER VALUE PARTNERS, LP
 --------------------------------------------------------------
 (b) Address of Principal Business Office, or if None, Residence:


 61 BROADWAY, NEW YORK, NY 10006


 --------------------------------------------------------------
 (c) Citizenship:
 NEW YORK STATE
 --------------------------------------------------------------
 (d) Title of Class of Securities:
 COMMON STOCK
 --------------------------------------------------------------
 (e) CUSIP Number:
 021152103
 --------------------------------------------------------------


Item 3. If this statement is filed pursuant to Rules 240.13d-(1), or
 13d-2(b) or (c), check whether the person filing is a:

 (a) [ ] Broker or Dealer registered under Section 15 of the
 Act, (15 U.S.C 78o)

 (b) [ ] Bank as defined in Section 3(a)(6) of the
 Act, (15 U.S.C 78c)

 (c) [ ] Insurance Company as defined in Section 3(a)(19) of
 the Act, (15 U.S.C 78c)

 (d) [ ] Investment Company registered under Section 8 of the
 Investment Company Act of 1940 (15 U.S.C 80a-8)

 (e) [ ] Investment Adviser in accordance with Section
 240.13d-1(b)(1)(ii)(E)

 (f) [ ] Employee Benefit Plan or endowment fund in accordance
 to Section 240.13d-1(b)(ii)(F)

 (g) [ ] A parent holding company or control person in
 accordance with Section 240.13d-1(b)(1)(ii)(G)


 (h) [ ] A savings associations as defined in Section 3(b) of the
 Federal Deposit Insurance Act (12 U.S.C 1813)

 (i) [ ] A church plan that is excluded from the definition of an
 investment company under section 3(c)(14) of
 the Investment Company Act of 1940 (15 U.S.C 80a-3)

 (j) [ ] Group, in accordance with Section 240.13d-1(b)(1)(ii)(J)



Item 4. Ownership.

 (a) Amount beneficially owned: 3,403,969----------,

 (b) Percent of class: 9.99%----------------------,

 (c) Number of shares as to which such person has:

 (i) Sole power to vote or to direct the vote
 3,403,969--,

 (ii) Shared power to vote or to direct the vote
 0------,

 (iii) Sole power to dispose or to direct the disposition of
 0-----,


 (iv) Shared power to dispose or to direct the disposition of
 3,403,969------


Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof
the reporting person has ceased to be the beneficial owner of more than five
percent of the class of securities, check the following [ ].
 INAPPLICABLE

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

 INAPPLICABLE

Item 7. Identification and Classification of the Subsidiary which Acquired
 the Security Being Reported on By the Parent Holding Company.

 INAPPLICABLE

Item 8. Identification and Classification of Members of the Group.

 INAPPLICABLE

Item 9. Notice of Dissolution of Group.

 INAPPLICABLE


Item 10. Certification.



 By signing below I certify that, to the best of my knowledge
and belief, the securities referred to above were acquired and are held in the
ordinary course of business and were not acquired and are not held for the
purpose of or with the effect of changing or influencing the control of the
issuer of the securities and were not acquired and are not held in connection
with or as a participant in any transaction having that purpose or effect.

 Signature.


 After reasonable inquiry and to the best of my knowledge and
 belief, I certify that the information set forth in this
 statement is true, complete and correct.

Date: 02/02/12

BY:INGALLS & SNYDER VALUE PARTNERS, LP

/s/ THOMAS O. BOUCHER, JR
----------------------------------
 (Signature)*

THOMAS O. BOUCHER, JR
----------------------------------
GENERAL PARTNER
 (Name/Title)

Alseres Pharmaceuticals (CE) (USOTC:ALSE)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024 Plus de graphiques de la Bourse Alseres Pharmaceuticals (CE)
Alseres Pharmaceuticals (CE) (USOTC:ALSE)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024 Plus de graphiques de la Bourse Alseres Pharmaceuticals (CE)